CytomX Therapeutics Inc (NASDAQ: CTMX) is 162.58% higher on its value in year-to-date trading and has touched a low of $1.04 and a high of $5.85 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CTMX stock was last observed hovering at around $4.37 in the last trading session, with the day’s loss setting it -0.3%.
Currently trading at $4.07, the stock is 72.24% and 77.00% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.39 million and changing -6.86% at the moment leaves the stock 146.08% off its SMA200. CTMX registered 139.41% gain for a year compared to 6-month gain of 223.02%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 97.57% loss in the last 1 month and extending the period to 3 months gives it a 178.77%, and is 149.69% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 33.43% over the week and 12.79% over the month.
CytomX Therapeutics Inc (CTMX) has around 122 employees, a market worth around $277.33M and $101.21M in sales. Profit margin for the company is -0.56%. Distance from 52-week low is 291.35% and -30.43% from its 52-week high.
The EPS is expected to shrink by -4286.00% this year.
CytomX Therapeutics Inc (CTMX) Top Institutional Holders
The shares outstanding are 67.31M, and float is at 66.88M with Short Float at 5.37%.
CytomX Therapeutics Inc (CTMX) Insider Activity
The most recent transaction is an insider sale by McCarthy Sean A.,the company’sCEO. SEC filings show that McCarthy Sean A. sold 20,223 shares of the company’s common stock on Mar 19 ’24 at a price of $2.09 per share for a total of $42175.0. Following the sale, the insider now owns 0.52 million shares.
CytomX Therapeutics Inc disclosed in a document filed with the SEC on Mar 19 ’24 that BELVIN MARCIA (SVP, Chief Scientific Officer) sold a total of 12,795 shares of the company’s common stock. The trade occurred on Mar 19 ’24 and was made at $2.09 per share for $26684.0. Following the transaction, the insider now directly holds 0.17 million shares of the CTMX stock.
Still, SEC filings show that on Mar 19 ’24, Landau Jeffrey B (Chief Business Officer) disposed off 6,562 shares at an average price of $2.09 for $13685.0. The insider now directly holds 110,060 shares of CytomX Therapeutics Inc (CTMX).
